225 related articles for article (PubMed ID: 32820040)
21. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
22. Identification of DHODH as a therapeutic target in small cell lung cancer.
Li L; Ng SR; Colón CI; Drapkin BJ; Hsu PP; Li Z; Nabel CS; Lewis CA; Romero R; Mercer KL; Bhutkar A; Phat S; Myers DT; Muzumdar MD; Westcott PMK; Beytagh MC; Farago AF; Vander Heiden MG; Dyson NJ; Jacks T
Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694929
[TBL] [Abstract][Full Text] [Related]
23. USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1.
Lin YT; Lin J; Liu YE; Chen YC; Liu ST; Hsu KW; Chen DR; Wu HT
Cells; 2022 Oct; 11(20):. PubMed ID: 36291159
[TBL] [Abstract][Full Text] [Related]
24.
Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a.
Sun Y; Hu B; Wang Q; Ye M; Qiu Q; Zhou Y; Zeng F; Zhang X; Guo Y; Guo L
Cell Death Dis; 2018 Jan; 9(2):85. PubMed ID: 29367594
[TBL] [Abstract][Full Text] [Related]
26. TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.
Ye M; Wei T; Wang Q; Sun Y; Tang R; Guo L; Zhu W
Biochem Biophys Res Commun; 2017 Apr; 486(2):349-356. PubMed ID: 28302484
[TBL] [Abstract][Full Text] [Related]
27. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
[TBL] [Abstract][Full Text] [Related]
28. HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
Minami T; Kijima T; Otani Y; Kohmo S; Takahashi R; Nagatomo I; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Kumanogoh A
Mol Cancer Ther; 2012 Apr; 11(4):830-41. PubMed ID: 22389470
[TBL] [Abstract][Full Text] [Related]
29. Human bone marrow-derived mesenchymal stem cell-secreted exosomes overexpressing microRNA-34a ameliorate glioblastoma development via down-regulating MYCN.
Wang B; Wu ZH; Lou PY; Chai C; Han SY; Ning JF; Li M
Cell Oncol (Dordr); 2019 Dec; 42(6):783-799. PubMed ID: 31332647
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
31. MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D; Beaulieu ME; Soucek L
Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
[No Abstract] [Full Text] [Related]
32. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
Wagner AH; Devarakonda S; Skidmore ZL; Krysiak K; Ramu A; Trani L; Kunisaki J; Masood A; Waqar SN; Spies NC; Morgensztern D; Waligorski J; Ponce J; Fulton RS; Maggi LB; Weber JD; Watson MA; O'Conor CJ; Ritter JH; Olsen RR; Cheng H; Mukhopadhyay A; Can I; Cessna MH; Oliver TG; Mardis ER; Wilson RK; Griffith M; Griffith OL; Govindan R
Nat Commun; 2018 Sep; 9(1):3787. PubMed ID: 30224629
[TBL] [Abstract][Full Text] [Related]
33. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy.
Sun Y; Shen W; Hu S; Lyu Q; Wang Q; Wei T; Zhu W; Zhang J
J Exp Clin Cancer Res; 2023 Mar; 42(1):65. PubMed ID: 36932427
[TBL] [Abstract][Full Text] [Related]
34. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
35. Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.
Schenk MW; Humphrey S; Hossain ASMM; Revill M; Pearsall S; Lallo A; Brown S; Bratt S; Galvin M; Descamps T; Zhou C; Pearce SP; Priest L; Greenhalgh M; Chaturvedi A; Kerr A; Blackhall F; Dive C; Frese KK
Nat Commun; 2021 Nov; 12(1):6652. PubMed ID: 34789728
[TBL] [Abstract][Full Text] [Related]
36. Role of mTOR As an Essential Kinase in SCLC.
Kern JA; Kim J; Foster DG; Mishra R; Gardner EE; Poirier JT; Rivard C; Yu H; Finigan JH; Dowlati A; Rudin CM; Tan AC
J Thorac Oncol; 2020 Sep; 15(9):1522-1534. PubMed ID: 32599072
[TBL] [Abstract][Full Text] [Related]
37. Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling.
Huang W; Yang Y; Wu J; Niu Y; Yao Y; Zhang J; Huang X; Liang S; Chen R; Chen S; Guo L
Cell Death Differ; 2020 May; 27(5):1709-1727. PubMed ID: 31728016
[TBL] [Abstract][Full Text] [Related]
38. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
[TBL] [Abstract][Full Text] [Related]
39. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression.
Zeng F; Wang Q; Wang S; Liang S; Huang W; Guo Y; Peng J; Li M; Zhu W; Guo L
Oncogene; 2020 Jan; 39(2):293-307. PubMed ID: 31477834
[TBL] [Abstract][Full Text] [Related]
40. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
